Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Section 6 of 6

References

198 sources

  1. Adler et al. (2025) (opens in a new tab)
  2. Agarwal et al. (2021) (opens in a new tab)
  3. Alnylam press release, ZENITH first patient dosed (2025) (opens in a new tab)
  4. AstraZeneca BAXFENDY prescribing information (2026) (opens in a new tab)
  5. AstraZeneca press release, baxdrostat NDA acceptance (2025) (opens in a new tab)
  6. AstraZeneca press release, Baxfendy EU CHMP opinion (2026) (opens in a new tab)
  7. AstraZeneca press release, BAXFENDY US approval (2026) (opens in a new tab)
  8. Azizi et al. (2021) (opens in a new tab)
  9. Azizi et al. (2023) (opens in a new tab)
  10. Azizi et al. (2026) (opens in a new tab)
  11. Baker (2026) (opens in a new tab)
  12. Bakris et al. (2024a) (opens in a new tab)
  13. Bakris et al. (2024b) (opens in a new tab)
  14. Beaney (2025) (opens in a new tab)
  15. Beyhaghi and Viera (2019) (opens in a new tab)
  16. Blood Pressure Lowering Treatment Trialists' Collaboration (2021) (opens in a new tab)
  17. Blumenthal et al. (2021) (opens in a new tab)
  18. Boehringer Ingelheim press release, EASi-KIDNEY update (2026) (opens in a new tab)
  19. Brown et al. (2020) (opens in a new tab)
  20. Bryant et al. (2023) (opens in a new tab)
  21. Burgos et al. (2025) (opens in a new tab)
  22. Calhoun et al. (2002) (opens in a new tab)
  23. Carey et al. (2018) (opens in a new tab)
  24. Carey et al. (2019) (opens in a new tab)
  25. Carris and Smith (2015) (opens in a new tab)
  26. Carris et al. (2016) (opens in a new tab)
  27. CDC About High Blood Pressure (2026) (opens in a new tab)
  28. CDC High Blood Pressure Facts (2026) (opens in a new tab)
  29. Chang et al. (2019) (opens in a new tab)
  30. ClinicalTrials.gov NCT02953132 (opens in a new tab)
  31. ClinicalTrials.gov NCT05001945 (opens in a new tab)
  32. ClinicalTrials.gov NCT05001945 results (opens in a new tab)
  33. ClinicalTrials.gov NCT05769608 (opens in a new tab)
  34. ClinicalTrials.gov NCT05968430 (opens in a new tab)
  35. ClinicalTrials.gov NCT06150924 (opens in a new tab)
  36. ClinicalTrials.gov NCT06150924 results (opens in a new tab)
  37. ClinicalTrials.gov NCT06153693 (opens in a new tab)
  38. ClinicalTrials.gov NCT06785454 (opens in a new tab)
  39. CMS 2027 Part C and D Star Ratings Technical Notes (2026) (opens in a new tab)
  40. CMS 2027 Star Ratings Measures and Weights (2026) (opens in a new tab)
  41. CMS decision memo, renal denervation for uncontrolled hypertension (2025) (opens in a new tab)
  42. CMS NADAC, amiloride 5 mg (2026) (opens in a new tab)
  43. CMS NADAC, BAXFENDY 2 mg (2026) (opens in a new tab)
  44. CMS NADAC, eplerenone 50 mg (2026) (opens in a new tab)
  45. CMS NADAC, spironolactone 25 mg (2026) (opens in a new tab)
  46. CMS National Coverage Determination 20.19, ambulatory blood pressure monitoring (2019) (opens in a new tab)
  47. Cohen et al. (2021) (opens in a new tab)
  48. Daugherty et al. (2012) (opens in a new tab)
  49. de la Sierra et al. (2011) (opens in a new tab)
  50. de la Sierra et al. (2024) (opens in a new tab)
  51. Deragon et al. (2025) (opens in a new tab)
  52. Desai et al. (2022) (opens in a new tab)
  53. Desai et al. (2025) (opens in a new tab)
  54. Dieleman et al. (2025) (opens in a new tab)
  55. Dixon et al. (2023) (opens in a new tab)
  56. Douma et al. (2008) (opens in a new tab)
  57. Durand et al. (2017) (opens in a new tab)
  58. Dwyer et al. (2026) (opens in a new tab)
  59. Earle et al. (2026) (opens in a new tab)
  60. Elbahloul et al. (2026) (opens in a new tab)
  61. Electronic Code of Federal Regulations, 21 CFR 312.21 (2026) (opens in a new tab)
  62. Eli Lilly ZEPBOUND prescribing information (2024) (opens in a new tab)
  63. Ettehad et al. (2016) (opens in a new tab)
  64. EU Clinical Trials Information System 2023-506425-12-00 (opens in a new tab)
  65. Fang et al. (2020) (opens in a new tab)
  66. FDA draft guidance, studies on a background of multiple antihypertensive drugs (2018) (opens in a new tab)
  67. FDA guidance, hypertension labeling for cardiovascular outcome claims (2011) (opens in a new tab)
  68. FDA guidance, ICH E1A extent of population exposure (1995) (opens in a new tab)
  69. FDA NDA 217686 supplement approval letter (2025) (opens in a new tab)
  70. FDA NDA 219878 approval letter (2026) (opens in a new tab)
  71. FDA PMA database, Paradise Ultrasound Renal Denervation System (2023) (opens in a new tab)
  72. FDA PMA database, Symplicity Spyral Renal Denervation System (2023) (opens in a new tab)
  73. FDA Table of Surrogate Endpoints (2026) (opens in a new tab)
  74. Fioretti et al. (2025) (opens in a new tab)
  75. Flack et al. (2024) (opens in a new tab)
  76. Flack et al. (2025) (opens in a new tab)
  77. Franklin et al. (2026) (opens in a new tab)
  78. Fryar et al. (2024) (opens in a new tab)
  79. Gaddam et al. (2008) (opens in a new tab)
  80. Geisler et al. (2012) (opens in a new tab)
  81. Gupta et al. (2017) (opens in a new tab)
  82. Henry et al. (2026) (opens in a new tab)
  83. ICER evidence report (2026) (opens in a new tab)
  84. ICER hypertension assessment page (2026) (opens in a new tab)
  85. ICER public comment folio (2026) (opens in a new tab)
  86. ICER public meeting slides (2026) (opens in a new tab)
  87. ICER response to public comments (2026) (opens in a new tab)
  88. Idorsia press release, aprocitentan commercialization partnership (2026) (opens in a new tab)
  89. Idorsia TRYVIO prescribing information (2026) (opens in a new tab)
  90. Jacob et al. (2017) (opens in a new tab)
  91. Jones et al. (2025) (opens in a new tab)
  92. Judge et al. (2025) (opens in a new tab)
  93. Kandzari et al. (2023) (opens in a new tab)
  94. Kandzari et al. (2024) (opens in a new tab)
  95. Kandzari et al. (2025) (opens in a new tab)
  96. Kazi et al. (2024) (opens in a new tab)
  97. Kirkland et al. (2018) (opens in a new tab)
  98. Krieger et al. (2018) (opens in a new tab)
  99. Laffin et al. (2023) (opens in a new tab)
  100. Laffin et al. (2025a) (opens in a new tab)
  101. Laffin et al. (2025b) (opens in a new tab)
  102. Lee et al. (2024) (opens in a new tab)
  103. Lee et al. (2025) (opens in a new tab)
  104. Lewington et al. (2002) (opens in a new tab)
  105. Lubitz et al. (2015) (opens in a new tab)
  106. MacLeod et al. (2022) (opens in a new tab)
  107. Mahfoud et al. (2022) (opens in a new tab)
  108. Malhotra et al. (2021) (opens in a new tab)
  109. Malhotra et al. (2024) (opens in a new tab)
  110. Mancia et al. (2023) (opens in a new tab)
  111. Martin et al. (2025) (opens in a new tab)
  112. McEvoy et al. (2024) (opens in a new tab)
  113. Mehra et al. (2026) (opens in a new tab)
  114. Million Hearts hypertension cascade (2023) (opens in a new tab)
  115. Mineralys Therapeutics first quarter 2026 results announcement (2026) (opens in a new tab)
  116. Mineralys Therapeutics Form 10-K (2026) (opens in a new tab)
  117. Mineralys Therapeutics Form 10-Q (2026) (opens in a new tab)
  118. Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026) (opens in a new tab)
  119. Mineralys Therapeutics fourth quarter 2025 results announcement (2026) (opens in a new tab)
  120. Mineralys Therapeutics pipeline (opens in a new tab)
  121. Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025) (opens in a new tab)
  122. Mineralys Therapeutics press release, Advance-HTN NEJM publication (2025) (opens in a new tab)
  123. Mineralys Therapeutics press release, AHA Hypertension 2026 (2026) (opens in a new tab)
  124. Mineralys Therapeutics press release, ASN Kidney Week 2025 (2025) (opens in a new tab)
  125. Mineralys Therapeutics press release, board appointments (2026) (opens in a new tab)
  126. Mineralys Therapeutics press release, corporate update (2026) (opens in a new tab)
  127. Mineralys Therapeutics press release, ENDO 2026 (2026) (opens in a new tab)
  128. Mineralys Therapeutics press release, ESH 2025 Launch-HTN presentation (2025) (opens in a new tab)
  129. Mineralys Therapeutics press release, ESH 2026 (2026) (opens in a new tab)
  130. Mineralys Therapeutics press release, Explore-CKD publication (2026) (opens in a new tab)
  131. Mineralys Therapeutics press release, Explore-CKD topline results (2025) (opens in a new tab)
  132. Mineralys Therapeutics press release, Explore-OSA trial initiation (2025) (opens in a new tab)
  133. Mineralys Therapeutics press release, Launch-HTN and Advance-HTN topline results (2025) (opens in a new tab)
  134. Mineralys Therapeutics press release, Launch-HTN JAMA publication (2025) (opens in a new tab)
  135. Mineralys Therapeutics press release, Launch-HTN subgroup analyses (2025) (opens in a new tab)
  136. Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026) (opens in a new tab)
  137. Mineralys Therapeutics press release, Tanabe royalty repurchase (2026) (opens in a new tab)
  138. Mineralys Therapeutics press release, Target-HTN JAMA publication (2023) (opens in a new tab)
  139. Mineralys Therapeutics press release, Target-HTN topline results (2022) (opens in a new tab)
  140. Mineralys Therapeutics press release, Transform-HTN late-breaker selection (2026) (opens in a new tab)
  141. Mineralys Therapeutics press release, Transform-HTN results (2026) (opens in a new tab)
  142. Mineralys Therapeutics second quarter 2026 results announcement (2026) (opens in a new tab)
  143. Mineralys Therapeutics third quarter 2025 results announcement (2025) (opens in a new tab)
  144. Mineralys Therapeutics third quarter 2026 earnings call transcript (2026) (opens in a new tab)
  145. Mineralys Therapeutics third quarter 2026 results announcement (2026) (opens in a new tab)
  146. Monticone et al. (2018) (opens in a new tab)
  147. Muntner et al. (2019) (opens in a new tab)
  148. Muntner et al. (2020) (opens in a new tab)
  149. NCD Risk Factor Collaboration (2021) (opens in a new tab)
  150. NCQA Blood Pressure Control for Patients With Hypertension measure (opens in a new tab)
  151. NCQA Controlling High Blood Pressure measure (opens in a new tab)
  152. Noubiap et al. (2019) (opens in a new tab)
  153. Owei et al. (2026) (opens in a new tab)
  154. Parati et al. (2021) (opens in a new tab)
  155. Pfizer ALDACTONE prescribing information (2025) (opens in a new tab)
  156. Pimenta et al. (2009) (opens in a new tab)
  157. Pollock (2025) (opens in a new tab)
  158. Queiroga et al. (2026) (opens in a new tab)
  159. Rabbitt et al. (2024) (opens in a new tab)
  160. Rasmussen et al. (2025) (opens in a new tab)
  161. Reddy et al. (2025) (opens in a new tab)
  162. S&P Global Market Intelligence (2026) (opens in a new tab)
  163. Sacks et al. (2001) (opens in a new tab)
  164. Saxena et al. (2025) (opens in a new tab)
  165. Saxena et al. (2026a) (opens in a new tab)
  166. Saxena et al. (2026b) (opens in a new tab)
  167. Saxena et al. supplementary appendix (2025) (opens in a new tab)
  168. Schlaich et al. (2022) (opens in a new tab)
  169. Shimbo et al. (2020) (opens in a new tab)
  170. Shimizu et al. (2024) (opens in a new tab)
  171. Sim et al. (2015) (opens in a new tab)
  172. Staplin et al. (2023) (opens in a new tab)
  173. Sullivan and Ghushchyan (2006) (opens in a new tab)
  174. Tajeu et al. (2016) (opens in a new tab)
  175. Taylor et al. (2025) (opens in a new tab)
  176. Teza et al. (2026) (opens in a new tab)
  177. Thomas et al. (2018) (opens in a new tab)
  178. Tortorici et al. (2024) (opens in a new tab)
  179. Trevisol et al. (2011) (opens in a new tab)
  180. Tsou et al. (2026) (opens in a new tab)
  181. Tuttle et al. (2024) (opens in a new tab)
  182. US Preventive Services Task Force (2021) (opens in a new tab)
  183. Velasco et al. (2015) (opens in a new tab)
  184. Vemulapalli et al. (2017) (opens in a new tab)
  185. Viatris INSPRA prescribing information (2025) (opens in a new tab)
  186. Victor et al. (2018) (opens in a new tab)
  187. Vogt et al. (2026) (opens in a new tab)
  188. Wallach et al. (2024) (opens in a new tab)
  189. Wang et al. (2024) (opens in a new tab)
  190. Weir et al. (2026) (opens in a new tab)
  191. WHO Drug Information (2022) (opens in a new tab)
  192. Williams et al. (2015) (opens in a new tab)
  193. Williams et al. (2018) (opens in a new tab)
  194. Woode et al. (2023) (opens in a new tab)
  195. World Health Organization hypertension fact sheet (2025) (opens in a new tab)
  196. Yousif et al. (2026) (opens in a new tab)
  197. Yusuf et al. (2026) (opens in a new tab)
  198. Zeijen et al. (2024) (opens in a new tab)